脑梗死采用阿托伐他汀联合肠溶阿司匹林预防复发临床价值探析.docVIP

脑梗死采用阿托伐他汀联合肠溶阿司匹林预防复发临床价值探析 　　[摘要] 目的 探讨脑梗死采用阿托伐他汀联合肠溶阿司匹林预防复发的临床价值。 方法 选择我院2011年5月～2012年6月经由CT或MRI确诊并收治的脑梗死患者，合计169例。随机分为临床组85例和对照组84例。所有患者均实施神经内科常规治疗，常规组应用阿司匹林治疗，临床组在常规组基础上加用阿托伐他汀。而后比照两组治疗后的甘油三酯、总胆固醇及高、低密度脂蛋白水平，并统计脑梗复发情况。 结果 临床组其总胆固醇、甘油三酯及低密度脂蛋白水平均显著低于常规组（P0.05），其高密度脂蛋白水平显著高于常规组，差异有统计学意义（P0.01）。临床组85例在治疗期间3例脑梗复发、复发率为3.53%；常规组84例在治疗期间9例复发，复发率为10.71%。两组比较临床组其复发率显著低于常规组（P0.05），差异有统计学意义。 结论 脑梗死采用阿托伐他汀联合肠溶阿司匹林可有效改善患者血脂水平，遏制血栓形成，预防脑梗死复发。 　　[关键词] 脑梗死；阿托伐他汀；阿司匹林 　　[中图分类号] R743.3 [文献标识码] B [文章编号] 2095-0616（2014）04-110-03 　　Clinical value of atorvastatin combined with enteric-coated aspirin in the prevention of cerebral infarction recurrence 　　ZHONG Guoqiu 　　Blood Purification Center，Peoples Hospital of Yuancheng District，Heyuan City，Heyuan 517000，China 　　[Abstract] Objective To explore the clinical value of atorvastatin combined with enteric-coated aspirin in the prevention of cerebral infarction recurrence. Methods 169 patients who were diagnosed with cerebral infarction by CT or MRI in our hospital from 2011 May to 2012 June were included and randomly divided into two groups with 85 cases in the clinical group and 84 cases in the control group. Neurological routine treatment was given to all patients. Besides that，enteric-coated aspirin was given to the control group while atorvastation and enteric-coated aspirin was given to the clinical group. The level of triglycerides， total cholesterol，and high and low density lipoprotein were compared between two groups after the treatment and recurrence of cerebral infarction was analyzed. Results The level of total cholesterol，triglycerides and low density lipoprotein in clinical group was lower than that in control group（P0.05） while the high density lipoprotein level in clinical group was higher than that in control group （P0.01）.The difference was statistically significant. During the treatment，3 cases had cerebral infarction with a recurrence rate of 3.53% in clinical group while 9 cases had cerebral infarction with